243 related articles for article (PubMed ID: 28847034)
1. Challenges to a Cure for HBV Infection.
Testoni B; Levrero M; Zoulim F
Semin Liver Dis; 2017 Aug; 37(3):231-242. PubMed ID: 28847034
[No Abstract] [Full Text] [Related]
2. Targeting the Achilles heel of the hepatitis B virus: a review of current treatments against covalently closed circular DNA.
Ahmed M; Wang F; Levin A; Le C; Eltayebi Y; Houghton M; Tyrrell L; Barakat K
Drug Discov Today; 2015 May; 20(5):548-61. PubMed ID: 25622780
[TBL] [Abstract][Full Text] [Related]
3. Antiviral strategies to eliminate hepatitis B virus covalently closed circular DNA (cccDNA).
Revill P; Locarnini S
Curr Opin Pharmacol; 2016 Oct; 30():144-150. PubMed ID: 27639371
[TBL] [Abstract][Full Text] [Related]
4. The molecular virology of hepatitis B virus.
Glebe D; Bremer CM
Semin Liver Dis; 2013 May; 33(2):103-12. PubMed ID: 23749666
[TBL] [Abstract][Full Text] [Related]
5. The current status and future directions of hepatitis B antiviral drug discovery.
Tang L; Zhao Q; Wu S; Cheng J; Chang J; Guo JT
Expert Opin Drug Discov; 2017 Jan; 12(1):5-15. PubMed ID: 27797587
[TBL] [Abstract][Full Text] [Related]
6. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B.
Wursthorn K; Lutgehetmann M; Dandri M; Volz T; Buggisch P; Zollner B; Longerich T; Schirmacher P; Metzler F; Zankel M; Fischer C; Currie G; Brosgart C; Petersen J
Hepatology; 2006 Sep; 44(3):675-84. PubMed ID: 16941693
[TBL] [Abstract][Full Text] [Related]
7. Upcoming pharmacological developments in chronic hepatitis B: can we glimpse a cure on the horizon?
Alonso S; Guerra AR; Carreira L; Ferrer JÁ; Gutiérrez ML; Fernandez-Rodriguez CM
BMC Gastroenterol; 2017 Dec; 17(1):168. PubMed ID: 29268704
[TBL] [Abstract][Full Text] [Related]
8. Impact of early viral kinetics on T-cell reactivity during antiviral therapy in chronic hepatitis B.
Lau GK; Cooksley H; Ribeiro RM; Powers KA; Shudo E; Bowden S; Hui CK; Anderson J; Sorbel J; Mondou E; Rousseau F; Lewin S; Perelson AS; Locornini S; Naoumov NV
Antivir Ther; 2007; 12(5):705-18. PubMed ID: 17713154
[TBL] [Abstract][Full Text] [Related]
9. Molecular virology of hepatitis B virus and targets for antiviral intervention.
Glebe D; König A
Intervirology; 2014; 57(3-4):134-40. PubMed ID: 25034480
[TBL] [Abstract][Full Text] [Related]
10. The direct and indirect roles of HBV in liver cancer: prospective markers for HCC screening and potential therapeutic targets.
Ringelhan M; O'Connor T; Protzer U; Heikenwalder M
J Pathol; 2015 Jan; 235(2):355-67. PubMed ID: 25196558
[TBL] [Abstract][Full Text] [Related]
11. Virological Basis for the Cure of Chronic Hepatitis B.
Hu J; Cheng J; Tang L; Hu Z; Luo Y; Li Y; Zhou T; Chang J; Guo JT
ACS Infect Dis; 2019 May; 5(5):659-674. PubMed ID: 29893548
[TBL] [Abstract][Full Text] [Related]
12. Chronic Hepatitis B Virus Infection: Disease Revisit and Management Recommendations.
Yuen MF; Ahn SH; Chen DS; Chen PJ; Dusheiko GM; Hou JL; Maddrey WC; Mizokami M; Seto WK; Zoulim F; Lai CL
J Clin Gastroenterol; 2016 Apr; 50(4):286-94. PubMed ID: 26840752
[TBL] [Abstract][Full Text] [Related]
13. Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alpha-2a and adefovir.
Takkenberg B; Terpstra V; Zaaijer H; Weegink C; Dijkgraaf M; Jansen P; Beld M; Reesink H
J Gastroenterol Hepatol; 2011 Oct; 26(10):1527-35. PubMed ID: 21557773
[TBL] [Abstract][Full Text] [Related]
14. CccDNA persistence during natural evolution of chronic VHB infection.
Caruntu FA; Molagic V
Rom J Gastroenterol; 2005 Dec; 14(4):373-7. PubMed ID: 16400354
[TBL] [Abstract][Full Text] [Related]
15. Baicalin benefits the anti-HBV therapy via inhibiting HBV viral RNAs.
Huang H; Zhou W; Zhu H; Zhou P; Shi X
Toxicol Appl Pharmacol; 2017 May; 323():36-43. PubMed ID: 28322895
[TBL] [Abstract][Full Text] [Related]
16. Control and Eradication Strategies of Hepatitis B Virus.
Shih C; Chou SF; Yang CC; Huang JY; Choijilsuren G; Jhou RS
Trends Microbiol; 2016 Sep; 24(9):739-749. PubMed ID: 27287929
[TBL] [Abstract][Full Text] [Related]
17. Covalently closed-circular hepatitis B virus DNA reduction with entecavir or lamivudine.
Bowden S; Locarnini S; Chang TT; Chao YC; Han KH; Gish RG; de Man RA; Yu M; Llamoso C; Tang H
World J Gastroenterol; 2015 Apr; 21(15):4644-51. PubMed ID: 25914474
[TBL] [Abstract][Full Text] [Related]
18. Emerging therapeutics and relevant targets for chronic Hepatitis B.
Song IH
Turk J Gastroenterol; 2016 May; 27(3):210-5. PubMed ID: 27210776
[TBL] [Abstract][Full Text] [Related]
19. Latest developments in the treatment of hepatitis B.
Dandri M; Petersen J
Minerva Gastroenterol Dietol; 2016 Mar; 62(1):88-102. PubMed ID: 26448309
[TBL] [Abstract][Full Text] [Related]
20. Impact of lamivudine-resistance mutations on entecavir treatment outcome in hepatitis B.
Koffi J; Egounlety R; Pradat P; Lebosse F; Si-Ahmed SN; Lussier V; Chevallier P; Bailly F; Zoulim F
Eur J Gastroenterol Hepatol; 2014 Feb; 26(2):146-54. PubMed ID: 24025974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
